

The Dow Jones Sustainability Index recognizes Grifols as one of the world's most sustainable companies

- *For the first time ever, Grifols has been included in the Dow Jones Sustainability Index (DJSI) Europe, ranking among the top 5 companies in its sector globally and the only European firm to appear in its category*
- *The world's leading sustainability index, the DJSI measures the performance of companies based on environmental, social and governance (ESG) dimensions. This year's report selected only 323 out of a total of more than 2,500 participating firms*

Barcelona, November 16, 2020.- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and one of the world's leading producers of plasma-derived medicines with more than 100 years of history contributing to improve people's health and well-being, has been recognized among the world's most sustainable companies by the Dow Jones Sustainability Index (DJSI), the largest global sustainability index and an international benchmark for socially responsible investors.

For the first time, Grifols appears in the Dow Jones Sustainability Index Europe, which evaluates firms' environmental, social and governance (ESG) performance. The company appears among the top 5 companies in its sector globally and is the only representative in its segment from Europe.

Grifols earned the highest possible score (100 points) in Environmental Reporting and Social Reporting dimensions. In Tax Strategy, the company achieves the largest score within its industry.

For the company's co-CEOs Raimon Grifols and Víctor Grifols Deu, "Being recognized on the world's most relevant sustainability index is a significant milestone, as well as a reflection of our vision of values-based, ethics and longstanding engagement to our employees.

We continue to move forward in our commitment to sustainable growth and a long-term vision, in which sustainability serves as a core pillar since the foundation of the company. Ethics, health and environment must go hand in hand. To this end, Grifols does its utmost to effectively respond to the needs of society while embracing a sustainable approach in how we meet them. This approach forms an integral part of our corporate culture and reflects the values instilled by our founders more than 100 years ago. Without a doubt, our success is the result of teamwork. In these challenging times, the perseverance, dedication and commitment of our team are a true inspiration. Thanks to the efforts of thousands of Grifols employees worldwide,

the company is able to continue providing life-saving therapies, products and services for patients who need them, as well as contribute to the fight against COVID-19.

This recognition of our transparency and reporting efforts encourages us to continue working in the same direction, convinced that the power of a job well done generates value.”

The DJSI is a global index that evaluates the ESG performance of thousands of publicly traded firms around the world. Of the 2,500 participating companies in 2020, only 323 were selected to appear on the index.

ESG indices are used by a broad range of financial market agents to guide their investment decisions.

Since 2018, Grifols has also been included in the FTSE4Good Global, FTSE4Good Europe and FTSE4Good Ibex sustainability stock market indices.

Investor contact:

Investor Relations

inversores@grifols.com - investors@grifols.com

Phone number: +34 93 571 02 21

Media contacts:

Raquel Lumbreras Raquel_lumbreras@duomocomunicacion.com

Borja Gómez Borja_gomez@duomocomunicacion.com

Duomo Comunicación – **Grifols PR office**

Tel. +34 91 311 92 89 - 91 311 92 90

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services that are sold in more than 100 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat chronic, rare and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 24,000 employees in 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2019, Grifols' economic impact in its core countries of operation was EUR 8.5 billion. The company also generated 148,000 jobs, including indirect and induced.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit www.grifols.com

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are "future projections and assumptions". Words and expressions such as "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "will seek to achieve", "it is estimated", "future" and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.